摘要
目的观察美托洛尔联合曲美他嗪治疗冠心病心力衰竭临床疗效。方法 选择2015年1年~2016年1月在我院治疗的冠心病心力衰竭患者60例为研究对象,随机分为干预组和对照组各30例,两组患者均予常规治疗,对照组在基础治疗上加用美托洛尔,观察组同时加用曲美他嗪,3个月为1个疗程。比较两组的临床疗效及LVEF、HR的变化情况。结果 观察组治疗后的总有效率为96.7%,对照组患者治疗后的总有效率为70.0%,观察组的临床疗效显著优于对照组,组间比较差异有统计学意义（P〈0.05）。治疗后,观察组与对照组患者的LVEF、HR较治疗前明显升高,其中观察组的LVEF、HR较对照组变化更显著,组间比较差异有统计学意义（P〈0.05）。结论将美托洛尔、曲美他嗪二者联合应用治疗冠心病心力衰竭可以提高临床疗效,改善心功能,缓解患者的临床症状,提高生存质量,值得临床推广和应用。
Objective To observe the effect of metoprolol combined with trimetazidine in treatment of coronary heart disease and heart failure. Methods A tatal of 60 patients with coronary heart disease and heart failure who were treated in our hospital from January 2015 to January 2016,were randomly divided into intervention group and control group, each of 30 cases. Patients were given conventional treatment, and the control group combind metoprolol, and the ob- servation group combind trimetazidine, 3 months for a course of treatment. The clinical effect and the changes of LVEF, HR were compared between the two groups. Results The total effective rate of observation group after treatment was 96.7%, the control group was 70.0%, the clinical efficacy of the observation group was significantly better than that of the control group,the difference was significant（P〈0.05）. After treatment, the LVEF, HR of observation group and control group patients were significantly higher than before treatment, the changes of observation group were more significantly higher than that of the control group, the difference was significant（P〈0.05）. Conclusion Sibutramine and trimetazidine in treatment of coronary heart disease and heart failure can improve the clinical efficacy, improve heart function, re- lieve the clinical symptoms of the patients, improve the quality of life, is worthy of extensive promotion and application.
出处
《中国现代医生》
2016年第29期36-38,共3页
China Modern Doctor
